Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Earnings for Cassava Sciences, Inc. (SAVA)
Earnings in 2023 (TTM): $-97,217,000
According to Cassava Sciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-97,217,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Cassava Sciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-97,217,000 | $-97,217,000 |
| 2022 | $-76,246,000 | $-72,472,000 |
| 2021 | $-32,385,000 | $-31,802,000 |
| 2020 | $-6,334,000 | $-5,854,000 |
| 2019 | $-4,631,000 | $-4,245,000 |
| 2018 | $-6,557,000 | $-6,557,000 |
| 2017 | $-11,911,000 | $-11,911,000 |
| 2016 | $-14,850,000 | $-14,850,000 |
| 2015 | $-14,145,000 | $-14,145,000 |
| 2014 | $-12,386,000 | $-12,386,000 |
| 2013 | $31.47 M | $31.54 M |
| 2012 | $-3,446,000 | $-3,446,000 |
| 2011 | $-2,613,000 | $-2,613,000 |
| 2010 | $-12,023,000 | $-12,023,000 |
| 2009 | $-4,977,000 | $-3,467,000 |
| 2008 | $14.73 M | $15.35 M |
| 2007 | $20.31 M | $20.31 M |
| 2006 | $9.12 M | $6.19 M |
| 2005 | $-30,670,000 | $-30,670,000 |
| 2004 | $-37,776,000 | $-37,776,000 |
| 2003 | $-21,617,000 | $-21,617,000 |
| 2002 | $-15,925,000 | $-15,925,000 |
| 2001 | $-14,336,550 | $-14,337,350 |
| 2000 | $-17,478,990 | $-17,479,790 |
| 1999 | $-4,498,785 | $-4,499,585 |